東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Lung cancer = new understandings and...

Chiang, Anne C.

Linked to FindBook

Google Book

Amazon

博客來

Lung cancer = new understandings and therapies /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Lung cancer/ edited by Anne C. Chiang, Roy S. Herbst.
Reminder of title:	new understandings and therapies /
other author:	Chiang, Anne C.
Published:	Cham :Springer International Publishing : : 2021.,
Description:	vi, 264 p. :ill. (some col.), digital ;24 cm.
[NT 15003449]:	Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- Biomarkers: is tumor mutational burden the new prognostic grail? -- Liquid biopsies: new technology and evidence -- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- What can we learn from acquired resistance? -- Management of Brain Metastases -- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- Therapeutic Advances in Small Cell Lung Cancer Management -- Small Cell Lung Cancer: Biology Advances -- Immunotherapy and Radiotherapy: New Strategies -- Ultimate Precision: Targeting Cancer but not Normal Self-Replication -- Index.
Contained By:	Springer Nature eBook
Subject:	Lungs - Cancer -
Online resource:	https://doi.org/10.1007/978-3-030-74028-3
ISBN:	9783030740283

Lung cancer = new understandings and therapies /
Lung cancernew understandings and therapies /[electronic resource] :edited by Anne C. Chiang, Roy S. Herbst. - Cham :Springer International Publishing :2021. - vi, 264 p. :ill. (some col.), digital ;24 cm. - Current cancer research,2199-2592. - Current cancer research..

Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- Biomarkers: is tumor mutational burden the new prognostic grail? -- Liquid biopsies: new technology and evidence -- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- What can we learn from acquired resistance? -- Management of Brain Metastases -- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- Therapeutic Advances in Small Cell Lung Cancer Management -- Small Cell Lung Cancer: Biology Advances -- Immunotherapy and Radiotherapy: New Strategies -- Ultimate Precision: Targeting Cancer but not Normal Self-Replication -- Index.

Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.

ISBN: 9783030740283

Standard No.: 10.1007/978-3-030-74028-3doiSubjects--Topical Terms:

2017391
Lungs
--Cancer

LC Class. No.: RC280.L8

Dewey Class. No.: 616.99424

Lung cancer = new understandings and therapies /
LDR:02328nmm a2200337 a 4500 001 2251525
003 DE-He213
005 20210930163851.0
006 m d
007 cr nn 008maaau
008 220215s2021 sz s 0 eng d
020 $a 9783030740283 $q (electronic bk.)
020 $a 9783030740276 $q (paper)
024 7 $a 10.1007/978-3-030-74028-3 $2 doi
035 $a 978-3-030-74028-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L8
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.99424 $2 23
090 $a RC280.L8 $b L963 2021
245 0 0 $a Lung cancer $h [electronic resource] : $b new understandings and therapies / $c edited by Anne C. Chiang, Roy S. Herbst.
260 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2021.
300 $a vi, 264 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Current cancer research, $x 2199-2592
505 0 $a Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- Biomarkers: is tumor mutational burden the new prognostic grail? -- Liquid biopsies: new technology and evidence -- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- What can we learn from acquired resistance? -- Management of Brain Metastases -- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- Therapeutic Advances in Small Cell Lung Cancer Management -- Small Cell Lung Cancer: Biology Advances -- Immunotherapy and Radiotherapy: New Strategies -- Ultimate Precision: Targeting Cancer but not Normal Self-Replication -- Index.
520 $a Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
650 0 $a Lungs $x Cancer $x Treatment. $3 2017391
650 1 4 $a Cancer Research. $3 891172
650 2 4 $a Molecular Medicine. $3 890952
650 2 4 $a Oncology. $3 751006
650 0 $a Lungs $x Cancer. $3 815892
700 1 $a Chiang, Anne C. $3 3518608
700 1 $a Herbst, Roy S. $3 3518609
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Current cancer research. $3 1566812
856 4 0 $u https://doi.org/10.1007/978-3-030-74028-3
950 $a Medicine (SpringerNature-11650)